PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 18, 2026Journal of Craniofacial Surgery0 citations

Fat Apoptosis Injection Therapy for Infraorbital Herniated Fat Pads

View Full Paper
TSTamara SemenovychIRIsabella RoselliniJMJessie L.J. Min

Key Points

  • The aim was to evaluate the feasibility and short-term outcomes of fat apoptosis injection therapy for infraorbital herniated fat pads.
  • Conducted an observational case series with 7 patients
  • Prepared fat apoptosis solution using ascorbic acid and ferrous gluconate
  • Administered injections at 3 sites per infraorbital region
  • Performed 1 to 3 treatment sessions at 7- to 14-day intervals
  • Evaluated outcomes with photographs, physician assessments, and patient-reported satisfaction.
  • All patients showed visible improvement in infraorbital contour
  • Improvements noted within 24 to 72 hours post-injection
  • Four patients had near-complete correction after 1 to 2 sessions
  • Three patients with severe herniation required up to 3 sessions with substantial improvement
  • Transient adverse events included erythema, edema, and tenderness, resolving within 72 hours.

Abstract

Background: Infraorbital herniated fat pads (“eyebags”) are a frequent aesthetic concern. Surgical blepharoplasty remains the gold standard but is associated with downtime and potential complications. Fat apoptosis (FA) injection therapy is a novel, minimally invasive approach that selectively induces adipocyte apoptosis, leading to volume reduction without surgical intervention. Objective: To describe the feasibility and short-term outcomes of FA injection therapy for infraorbital herniated fat pads in a small observational case series. Methods: This was an observational case series of 7 patients with infraorbital herniation who underwent FA injection therapy. The FA solution was prepared by combining ascorbic acid and ferrous gluconate in a 1:9 ratio. Injections were administered using a 30- to 32-gauge needle at 3 sites per infraorbital region (0.1–0.2 mL per site). Patients received 1 to 3 treatment sessions at 7- to 14-day intervals, depending on baseline severity and clinical response. Outcomes were evaluated using standardized photographs, physician assessment of contour improvement, patient-reported satisfaction, and documentation of adverse events. Follow-up in this series was short-term (maximum 2–3 wk), and no blinded photographic assessment or validated patient-reported outcome measure was used. Results: All patients demonstrated visible improvement in infraorbital contour. Early changes were observed within 24 to 72 hours postinjection, with progressive refinement over 2 to 3 weeks. Four patients with mild-to-moderate herniation achieved near-complete correction after 1 to 2 sessions. Three patients with severe herniation required up to 3 sessions and showed substantial, though partial, improvement. Adverse events were limited to transient erythema, edema, and tenderness in 7 patients, resolving spontaneously within 72 hours. No necrosis, ulceration, pigmentary alteration, or systemic complications were reported. Patient satisfaction was high, with 5 patients (71%) rating their results as “very satisfactory” and 2 (29%) as “satisfactory.” Conclusion: In this small case series with short-term follow-up, FA injection therapy was feasible and well tolerated and was associated with visible short-term improvement in infraorbital contour. These findings are hypothesis-generating; larger controlled studies with validated outcome instruments (eg, FACE-Q) and longer safety follow-up are required before definitive conclusions regarding efficacy, durability, and late complications can be drawn.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Semenovych et al. (2026) studied this question.

synapsesocial.com/papers/69ba428e4e9516ffd37a2da2https://doi.org/10.1097/scs.0000000000012566
Ask AI
Helpful
Bookmark
Share
View Full Paper